Association of IL-21 cytokine with severity of primary sjögren syndrome dry eye

Cornea

Volumn 34, Issue 3, 2015, Pages 248-252

  Lim, Sung A ^a,b   Nam, Doo Hyun ^c   Lee, Jee Hye ^a   Kwok, Seung Ki ^d   Park, Sung Hwan ^d   Chung, So Hyang ^a,b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Northfield Mount Hermon School   (United States)

^d Center for Environmental Toxico Genomics and Proteomics   (South Korea)

Author keywords

Conjunctiva; Dry eye; IL 21; Primary Sj gren syndrome; Tear

Indexed keywords

INTERLEUKIN 21; MESSENGER RNA; INTERLEUKIN-21; INTERLEUKINS;

ADULT; ARTICLE; CONJUNCTIVA; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRY EYE; EYE DISEASE ASSESSMENT; FEMALE; FLOW CYTOMETRY; HUMAN; IMPRESSION CYTOLOGY; MAJOR CLINICAL STUDY; MALE; OCULAR SURFACE DISEASE INDEX; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SJOEGREN SYNDROME; TEAR FILM; AGED; CASE-CONTROL STUDIES; DRY EYE SYNDROMES; GENE EXPRESSION PROFILING; HUMANS; METABOLISM; MIDDLE AGED; PATHOLOGY; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME; TEARS;

ADULT; AGED; CASE-CONTROL STUDIES; CONJUNCTIVA; DRY EYE SYNDROMES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME; TEARS;

EID: 84923555329     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0000000000000363     Document Type: Article

References (39)

1. Fox RI. Sjögren's syndrome. Lancet. 2005;366:321-331.
2. Skopouli FN, Fox PC, Galanopoulou V, et al. T cell subpopulations in the labial minor salivary gland histopathologic lesion of Sjögren's syndrome. J Rheumatol. 1991;18:210-214.
3. Stern ME, Gao J, Schwalb TA, et al. Conjunctival T-cell subpopulations in Sjögren's and non-Sjögren's patients with dry eye. Invest Ophthalmol Vis Sci. 2002;43:2609-2614.
4. Pflugfelder SC, Huang AJ, Feuer W, et al. Conjunctival cytologic features of primary Sjögren's syndrome. Ophthalmology. 1990;97:985-991.
5. Xu KP, Katagiri S, Takeuchi T, et al. Biopsy of labial salivary glands and lacrimal glands in the diagnosis of Sjögren's syndrome. J Rheumatol. 1996;23:76-82.
6. Tsubota K, Toda I, Yagi Y, et al. Three different types of dry eye syndrome. Cornea. 1994;13:202-209.
7. Gong YZ, Nititham J, Taylor K, et al. Differentiation of follicular helper T cells by salivary gland epithelial cells in primary Sjögren's syndrome. J Autoimmun. 2014;51:57-66.
8. Ettinger R, Kuchen S, Lipsky PE. Interleukin 21 as a target of intervention in autoimmune disease. Ann Rheum Dis. 2008;67(suppl 3):iii83-iii86.
9. Leonard WJ. Cytokines and immunodeficiency diseases. Nat Rev Immunol. 2001;1:200-208.
10. Chisholm DM, Mason DK. Labial salivary gland biopsy in Sjögren's disease. J Clin Pathol. 1968;21:656-660.
11. Kang KY, Kim HO, Kwok SK, et al. Impact of interleukin-21 in the pathogenesis of primary Sjögren's syndrome: increased serum levels of interleukin-21 and its expression in the labial salivary glands. Arthritis Res Ther. 2011;13:R179.
12. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554-558.
13. Delaleu N, Jonsson MV, Appel S, et al. New concepts in the pathogenesis of Sjögren's syndrome. Rheum Dis Clin North Am. 2008; 34:833-845.
14. Hwang J, Chung SH, Jeon S, et al. Comparison of clinical efficacies of autologous serum eye drops in patients with primary and secondary Sjögren syndrome. Cornea. 2014;33:663-667.
15. Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea. 2003;22:640-650.
16. Lee SY, Han SJ, Nam SM, et al. Analysis of tear cytokines and clinical correlations in Sjögren syndrome dry eye patients and non-Sjögren syndrome dry eye patients. Am J Ophthalmol. 2013;156:247-253.
17. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT. Methods. 2001;25:402-408.
18. Tzioufas AG, Wassmuth R, Dafni UG, et al. Clinical, immunological, and immunogenetic aspects of autoantibody production against Ro/SSA, La/SSB and their linear epitopes in primary Sjögren's syndrome (pSS): a European multicentre study. Ann Rheum Dis. 2002;61:398-404.
19. Roescher N, Tak PP, Illei GG. Cytokines in Sjögren's syndrome. Oral Dis. 2009;15:519-526.
20. Varin MM, Le Pottier L, Youinou P, et al. B-cell tolerance breakdown in Sjögren's syndrome: focus on BAFF. Autoimmun Rev. 2010;9:604-608.
21. Tobón GJ, Pers JO, Youinou P, et al. B cell-targeted therapies in Sjögren's syndrome. Autoimmun Rev. 2010;9:224-228.
22. Lopez Bernal D, Ubels JL. Artificial tear composition and promotion of recovery of the damaged corneal epithelium. Cornea. 1993;12:115-120.
23. Solomon A, Dursun D, Liu Z, et al. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci. 2001;42:2283-2292.
24. Pflugfelder SC, Jones D, Ji Z, et al. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca. Curr Eye Res. 1999;19:201-211.
25. Lemp MA. Dry eye (Keratoconjunctivitis Sicca), rheumatoid arthritis, and Sjögren's syndrome. Am J Ophthalmol. 2005;140:898-899.
26. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol. 2011; 29:621-663.
27. Eto D, Lao C, DiToro D, et al. IL-21 and IL-6 are critical for different aspects of B cell immunity and redundantly induce optimal follicular helper CD4 T cell (Tfh) differentiation. PLoS One. 2011;6:e17739.
28. Sarra M, Monteleone G. Interleukin-21: a new mediator of inflammation in systemic lupus erythematosus. J Biomed Biotechnol. 2010;2010: 294582.
29. Spolski R, Kashyap M, Robinson C, et al. IL-21 signaling is critical for the development of type I diabetes in the NOD mouse. Proc Natl Acad Sci U S A. 2008;105:14028-14033.
30. Young DA, Hegen M, Ma HL, et al. Blockade of the interleukin- 21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum. 2007;56:1152-1163.
31. Scofield RH. IL-21 and Sjögren's syndrome. Arthritis Res Ther. 2011;13:137.
32. Kang EH, Lee YJ, Hyon JY, et al. Salivary cytokine profiles in primary Sjögren's syndrome differ from those in non-Sjögren sicca in terms of TNF-a levels and Th-1/Th-2 ratios. Clin Exp Rheumatol. 2011;29:970-976.
33. Sullivan BD, Whitmer D, Nichols KK, et al. An objective approach to dry eye severity. Invest Ophthalmol Vis Sci. 2010;51:6125-6130.
34. Zheng X, Bian F, Ma P, et al. Induction of Th17 differentiation by corneal epithelial-derived cytokines. J Cell Physiol. 2010;222: 95-102.
35. Katsifis GE, Rekka S, Moutsopoulos NM, et al. Systemic and local interleukin-17 and linked cytokines associated with Sjögren's syndrome immunopathogenesis. Am J Pathol. 2009;175:1167-1177.
36. Liu H, Liu G, Gong L, et al. Local suppression of IL-21 in submandibular glands retards the development of Sjögren's syndrome in non-obese diabetic mice. J Oral Pathol Med. 2012;41:728-735.
37. Chen YT, Nikulina K, Lazarev S, et al. Interleukin-1 as a phenotypic immunomodulator in keratinizing squamous metaplasia of the ocular surface in Sjögren's syndrome. Am J Pathol. 2010;177:1333-1343.
38. Yoon KC, Jeong IY, Park YG, et al. Interleukin-6 and tumor necrosis factor-alpha levels in tears of patients with dry eye syndrome. Cornea. 2007;26:431-437.
39. Tishler M, Yaron I, Geyer O, et al. Elevated tear interleukin-6 levels in patients with Sjögren syndrome. Ophthalmology. 1998;105:2327-2329.